Avivagen Inc. (VIV:TSX.V) announced in a news release it is exploring partnerships or other collaborations with cannabis producers to co-develop products that combine its proprietary OxC-beta technology with cannabis for the companion animal and other markets.
This decision comes after the multiple, large cannabis producers have expressed to Avivagen an interest in merging their expertise to create new offerings. "Avivagen has conducted a preliminary business analysis and believes that there are various combinations which could result in attractive product profiles, including based on distinct mechanisms of action between cannabis-based products and Avivagen's OxC-beta," the release noted.
Potentially, OxC-beta could be paired with hemp, cannabinoids, synthetic products, oils and extracts, and other cannabidiol- and tetrahydrocannabinol-based products.
Avivagen will only seek partners that are operating legally in their jurisdiction and have the requisite cannabis licensing.
"We are enthusiastic about working with leading edge cannabis companies and participating in their development of a line of products which incorporate our unique OxC-beta™ technology," says Kym Anthony, chairman and interim CEO of Avivagen. "We have been vocal advocates for the benefits of new product categories and look forward to collaborating with these large, well-resourced and innovative companies to bring these innovative products to the worldwide market, where appropriate."
Read what other experts are saying about:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.